title: Transforming growth factor-alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver.
abstract: BACKGROUND
  Hepatitis B virus (HBV) infection is closely associated with the development of hepatocellular carcinoma (HCC) in many patients, but the mechanisms by which HBV contributes to HCC are not known. Transforming growth factor-alpha (TGF-alpha), a regulator of growth and regeneration in rat liver that can be found in high levels in some human cancers, theoretically could play such an intermediate role in the development of HCC.
  
  
  METHODS
  The expression of TGF-alpha and its relation to the HBV antigens were evaluated in human HCC and adjacent nontumorous livers from 33 patients from the United States and China using immunoperoxidase staining of paraffin-embedded sections.
  
  
  RESULTS
  TGF-alpha was detected in HCC from 27 of 33 (82%) patients; the frequencies were similar in patients from the United States and China. TGF-alpha was detected in HCC more frequently in patients whose adjacent nontumorous livers had detectable hepatitis B surface antigen (HBsAg) and/or hepatitis B core antigen (HBcAg) than in those whose adjacent livers lacked HBsAg and HBcAg. Detection of TGF-alpha was not affected by tumor size, histologic type, or grade. TGF-alpha was detected in adjacent nontumorous livers from 31 of 33 patients (94%). Coexpression at a high intensity of TGF-alpha and HBsAg in the same hepatocytes could be demonstrated by specific staining of consecutively cut sections for 17 of 33 patients (52%).
  
  
  CONCLUSIONS
  TGF-alpha is expressed at a high level in 82% of human HCC. Localization of HBsAg within the same hepatocytes as TGF-alpha suggests a possible interaction between HBV and TGF-alpha during hepatocarcinogenesis in humans. Stimulation of TGF-alpha expression could be part of a chain of events by which HBV contributes to the development of HCC in some patients.
authors.affiliation: Biological Carcinogenesis Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: C C
authors.initials: CC
authors.lastname: Hsia
authors.forename: C A
authors.initials: CA
authors.lastname: Axiotis
authors.forename: A M
authors.initials: AM
authors.lastname: Di Bisceglie
authors.forename: E
authors.initials: E
authors.lastname: Tabor
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000737:chemistry* / Q000276:immunology / Q000473:pathology; D002454:Cell Differentiation; D002681:China / Q000453:epidemiology; D005260:Female; D006509:Hepatitis B / Q000150:complications; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006515:Hepatitis B virus; D006801:Humans; D007150:Immunohistochemistry; D008099:Liver / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism; D008113:Liver Neoplasms / Q000737:chemistry* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D016211:Transforming Growth Factor alpha / Q000032:analysis* / Q000502:physiology; D014481:United States / Q000453:epidemiology
chemical_list: D006514:Hepatitis B Surface Antigens; D016211:Transforming Growth Factor alpha